Evidence map›Paper›PMID 39770217›Full record

ArticleMicromachines2024

Intestinal Cells-on-Chip for Permeability Studies.

Marit Keuper-Navis, Hossein Eslami Amirabadi, Joanne Donkers, Markus Walles, Birk Poller, Bo Heming, Lisanne Pieters, Bjorn de Wagenaar, Adam Myszczyszyn, Theo Sinnige and 3 more

Abstract read
In one paragraph

Article in Micromachines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marit Keuper-NavisDepartment of Metabolic Health Research, Netherlands Organisation for Applied Scientific Research (TNO), 2333 BE Leiden, The Netherlands.
Hossein Eslami AmirabadiAZAR Innovations, 3584 CH Utrecht, The Netherlands.ORCID 0000-0001-7940-5833
Joanne DonkersDepartment of Metabolic Health Research, Netherlands Organisation for Applied Scientific Research (TNO), 2333 BE Leiden, The Netherlands.ORCID 0000-0002-3280-4703
Markus WallesPharmacokinetic Sciences, Biomedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland.ORCID 0000-0001-8376-8311
Birk PollerPharmacokinetic Sciences, Biomedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland.ORCID 0000-0002-1181-7572
Bo HemingDepartment of Metabolic Health Research, Netherlands Organisation for Applied Scientific Research (TNO), 2333 BE Leiden, The Netherlands.ORCID 0009-0001-4913-6692
Lisanne PietersDepartment of Metabolic Health Research, Netherlands Organisation for Applied Scientific Research (TNO), 2333 BE Leiden, The Netherlands.
Bjorn de WagenaarTNO Holst Centre, 5656 AE Eindhoven, The Netherlands.
Adam MyszczyszynDepartment of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, 3584 CT Utrecht, The Netherlands.ORCID 0009-0006-6152-5451
Theo SinnigeInstitute for Risk Assessment Sciences (IRAS), Utrecht University, 3584 CT Utrecht, The Netherlands.
Bart SpeeDepartment of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, 3584 CT Utrecht, The Netherlands.ORCID 0000-0002-8114-0560
Rosalinde MasereeuwDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584 CG Utrecht, The Netherlands.ORCID 0000-0002-1560-1074
Evita van de SteegDepartment of Metabolic Health Research, Netherlands Organisation for Applied Scientific Research (TNO), 2333 BE Leiden, The Netherlands.

Funding

Health∼Holland, Top Sector Life Sciences & Health LSHM20045-SGF
6 · The paper itself

Abstract

backgroundTo accurately measure permeability of compounds in the intestine, there is a need for preclinical in vitro models that accurately represent the specificity, integrity and complexity of the human small intestinal barrier. Intestine-on-chip systems hold considerable promise as testing platforms, but several characteristics still require optimization and further development.

methodsAn established intestine-on-chip model for tissue explants was adopted for intestinal cell monolayer culture. A 3D-printed culture disc was designed to allow cell culture in static conditions and subsequent permeability studies in a dynamic environment. Membrane characteristics and standardized read-outs were investigated and compared to traditional permeability studies under static conditions.

resultsBy starting cultures outside the chip in conventional wells plates, the new cell disc design could support accurate cell monolayer formation for both Caco-2 and human enteroids. When transferred to the chip with laminar flow, there was accurate detection of barrier integrity (FD4 and Cascade Blue) and permeability (atenolol/antipyrine). Both flow and membrane characteristics had a significant impact on permeability outcomes.

conclusionsThis novel intestinal cell-on-chip system offers large flexibility for intestinal permeability studies, although it still requires validation with more compounds to reveal its full potential.

Indexed as

cell monolayerintestinal absorptionintestinal barrierintestine-on-chipin vitro modelpermeability

Identifiers

PMID39770217
PMCPMC11679574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.